York PA 非小细胞肺癌临床试验
15项针对 非小细胞肺癌的研究正在 York及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- Cancer Care Associates Of York /ID# 270971, York
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- WellSpan Health-York Cancer Center, York
- WellSpan Health-York Hospital, York
- UPMC Memorial, York
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- WellSpan York Cancer Center, York
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
招募中3 期
- WellSpan Oncology Research, York
Pan-tumor MRD Study
招募中观察性研究
- Cancer Care Associates of York (CCAY), York
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
招募中3 期
- WellSpan Oncology Research, York
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
招募中3 期
- Research Site, York
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
招募中观察性研究
- WellSpan Medical Oncology & Hematology at York Cancer Center, York
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
招募中2 期
- WellSpan Health-York Cancer Center, York
- UPMC Memorial, York
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- Cancer Care Associates of York, York
- WellSpan Health-York Cancer Center, York
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
招募中2/3 期
- Cancer Care Associates of York, York
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- Cancer Care Associates of York, York
- WellSpan Health-York Cancer Center, York
- WellSpan Health-York Hospital, York
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
招募中观察性研究
- WellSpan Health - York Cancer Center, York
GEMINI-NSCLC: NSCLC Biomarker Study
招募中观察性研究
- Cancer Care Associates of York, York
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
招募中1/2 期
- Cancer Care Associates of York (site 206), York
其他城市的 非小细胞肺癌试验
- Houston, TX145 项研究
- New York City, NY121 项研究
- Arlington, VA104 项研究
- Nashville, TN97 项研究
- Boston, MA90 项研究
- Los Angeles, CA87 项研究
- St. Louis, MO73 项研究
- Chicago, IL61 项研究
- Baltimore, MD60 项研究
- San Antonio, TX59 项研究
- Columbus, OH57 项研究
- Washington, DC55 项研究
York的其他研究
- 癌症（所有类型）8 项研究
- 乳腺癌8 项研究
- 肺癌8 项研究
- 头颈鳞状细胞癌7 项研究
- 卵巢癌6 项研究
- 前列腺癌5 项研究
- 冠状动脉疾病5 项研究
- 食管癌4 项研究
- 三阴性乳腺癌4 项研究
- 结直肠癌4 项研究
- 子宫内膜癌4 项研究
- 结肠癌3 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。